GT, Goodwin act as Japan's Ono buys U.S. drugmaker for $2.4 bln
Greenberg Traurig has represented Japan’s Ono Pharmaceutical Co on its $2.4 billion acquisition of U.S.-based cancer drugmaker Deciphera, which was advised by Goodwin Procter.
BKK: Chandler MHM beefs up cap markets expertise with A&O Shearman hire
Thailand’s Chandler MHM had welcomed capital markets expert Doungporn Prasertsomsuk as a partner and co-head of its capital markets practice from A&O Shearman, where she was a counsel.
White & Case adds Linklaters funds pro in Tokyo
Global law firm White & Case has bolstered its investment funds offering in Tokyo with the addition of partner Eriko Sakata from Linklaters.
Trilegal counsel becomes JSA’s third partner hire in a month
Indian law firm J. Sagar Associates continued its hiring streak with the addition of Anurag Shrivastav as a partner in the firm’s corporate practice. Shrivastav was previously a counsel at Trilegal.
SG: Links adds India-focused PE funds expert from White & Case
Magic Circle law firm Linklaters has bolstered its India-facing corporate offering by hiring private equity funds specialist Sayak Maity as a partner in Singapore from White & Case.
As U.S. takes aim at Chinese biotech giants, lawyers warn of ‘dramatic impact’
The United States has extended its sprawling trade and technology control regime to cover the biotechnology sector as it is determined to “de-risk” from China.
R&T, WongP, Lee & Lee advise on $595 mln TCM deal
Singapore law firms WongPartnership, Lee & Lee and Rajah & Tann (R&T), and R&T’s Malaysian member firm Christopher & Lee Ong have advised traditional Chinese medicine firm Eu Yan Sang International (EYS) and its shareholders on the sale of 86 percent of EYS’ shares.
Haiwen, CC advise on China TCM's $2 bln take-private deal
Sinopharm Group, an investment consortium led by Sinopharm Group, and China Traditional Chinese Medicine Holdings (China TCM) recently announced a take-private deal for the Hong Kong-listed China TCM through a scheme of arrangement.
CC, Davis Polk act on ChaPanda’s $330 mln Hong Kong IPO
Davis Polk & Wardwell and Jingtian & Gongcheng have advised Sichuan Baicha Baidao, a Chinese low-priced tea chain also known as ChaPanda, on its $330 million IPO on the Hong Kong Stock Exchange, with Clifford Chance and King & Wood Mallesons acting for the sponsor CICC and underwriters.
CC, Slaughters advise as HK-listed SciClone goes private for $1.13 bln
Clifford Chance has advised the Hong Kong-listed SciClone Pharmaceuticals on an offer to take it private by healthcare-focused private equity firm GL Capital, with Slaughter and May acting for the buyer’s financial adviser, Capital Corporation Hong Kong Securities (CICC).